Celltrion
Celltrion to Conduct Trial of Remsima as COVID-19 Therapeutics in UK
Celltrion Healthcare announced on Wednesday that it would commence clinical trials of Remsima, an anti-inflammatory biosimilar, on COVID-19 patients this month...
Celltrion’s CT-P59 Antiviral Candidate Reduces COVID-19 Virus 100-Fold
Celltrion announced on Monday that its antiviral treatment candidate CT-P59 for COVID-19 positively lowered the amount of SARS-CoV-2 virus in...
Celltrion at Second Stage of Vaccine Development Against COVID-19
Celltrion said on Thursday that the company started to select through screening the most effective antibodies to neutralize the virus....
Celltrion to Conduct Trials for COVID-19 Test Kit, Cure in Six months
Celltrion, South Korea’s leading biosimilar developer, said it doubled its efforts to create a super-fast test kit designed to identify...
Celltrion to Establish China’s Biggest Biologics Plant
Celltrion announced on Tuesday that the company would establish its first plant in Wuhan, China, stating that the facility would...
